From Yahoo Finance: 2025-05-29 00:32:00

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) licenses the Gibson SOLA system from Telesis Bio Inc. to revolutionize DNA and gene synthesis, drastically reducing drug discovery time from weeks to hours. This move aligns with the trend of in-house synthetic biology tools in the biotech sector, enhancing data security and R&D efficiency.

Analysts are optimistic about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s growth potential with the adoption of the Gibson SOLA platform. Despite minimal stock movement post-clinical updates, long-term projections suggest increased earnings and revenue. However, some investors prefer AI stocks for higher returns and minimal risk compared to REGN.

Read more: Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency